Dr. Kazemi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2305 Camino Ramon
Suite 270
San Ramon, CA 94583Phone+1 925-866-8700Fax+1 925-866-8701
Education & Training
University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2006- University of California (San Francisco)Residency, Internal Medicine, 2000 - 2003
- University of California San Francisco School of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2002 - 2026
NJ State Medical License 2021 - 2025- National Board of Physicians and Surgeons Endocrinology Diabetes and Metabolism
- National Board of Physicians and Surgeons Internal Medicine
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
Publications & Presentations
PubMed
- 177 citationsMechanisms of triglyceride accumulation in activated macrophagesKenneth R. Feingold, Judy K. Shigenaga, Mahmood R. Kazemi, Carol M. McDonald, Sophie Patzek
Journal of Leukocyte Biology. 2012-10-01 - 37 citationsADRP/ADFP and Mal1 expression are increased in macrophages treated with TLR agonistsKenneth R. Feingold, Mahmood R. Kazemi, Amy L. Magra, Carol M. McDonald, Lisa G. Chui
Atherosclerosis. 2010-03-01 - 32 citationsThe Relationship between Nucleoside Analogue Treatment Duration, Insulin Resistance, and Fasting Arterialized Lactate Level in Patients with HIV InfectionJoan C. Lo, Mahmood R. Kazemi, Priscilla Y. Hsue, Jeffrey N. Martin, Steven G. Deeks
Clinical Infectious Diseases. 2005-11-01
Authored Content
- Mahmood Kazemi: A Remote Revolution in Diabetes CareNovember 2020
Press Mentions
Abbott Reports Positive Data from FreeStyle Libre 2 System TrialOctober 7th, 2022- ADA: Abbott's FreeStyle Libre 3 Scores Highest Accuracy for a 14-Day CGM in Clinical TrialJune 6th, 2022
- Late-Breaking Data Demonstrate Abbott’s FreeStyle Libre® 3 System Is Most Accurate 14-Day Continuous Glucose MonitorJune 5th, 2022
- Join now to see all
Professional Memberships
- Member
Other Languages
- French, Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
